A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2014
PF-06342674 (RN168), being developed for the treatment of multiple sclerosis (MS), is an antibody that binds to and inhibits the human interleukin-7 receptor, a component potentially involved in MS. PF-06342674 (RN168) is expected to play a role in slowing down the progression of the disease.
Epistemonikos ID: ca3454b6023436271286624e94a3765710d4a0ae
First added on: Mar 31, 2022